Maik Spreer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maik Spreer has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Petzold
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Technische Universität Dresden, Dresden, Deutschland
8 shared publications - Maximilian Pilhatsch
Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
6 shared publications - Max Schallenberg
Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital Dresden, Carl Gustav Carus Faculty of Medicine Dresden, Dresden University of Technology, Dresden, Germany
4 shared publications - Diana Vogel-Blaschka
Department of Psychiatry and Psychotherapy, Elblandklinikum Radebeul, Radebeul, Germany
3 shared publications - Ulrich Zimmermann
Klinik für Suchtmedizin und Psychotherapie, kbo Isar-Amper-Klinikum Region München, Klinik für Suchtmedizin und Psychotherapie, Haar, Germany
3 shared publications - Christoph U. Correll
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Der Nervenarzt
- Vol. 97 (6) , 600-602
Elektrokonvulsionstherapie bei jahrzehntelang therapieresistenter schizoaffektiver Störung: Remission und Wiedererlangung der Einwilligungsfähigkeit
- 7 September 2026
- Published by Springer Nature in Der Nervenarzt
- Vol. 97 (6) , 600-602
Open AccessElektrokonvulsionstherapie bei jahrzehntelang therapieresistenter schizoaffektiver Störung: Remission und Wiedererlangung der Einwilligungsfähigkeit
- 17 December 2025
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (02) , 88-96
Ergebnisse zu „Mama denk an mich“: Ein Versorgungsprogramm für methamphetaminabhängige Mütter und Väter
Zusammenfassung: Methamphetamin(MA)-Konsum hat ab etwa 2008 in einigen Regionen Deutschlands stark zugenommen, auch unter jungen Frauen im gebärfähigen Alter. Einerseits birgt MA-Konsum hohe Risiken für Mutter und Kind. Andererseits bieten Schwangerschaft und Elternschaft eine Chance, Betroffene in Therapien zu integrieren, die wegen unzureichender spezifischer Therapiemöglichkeiten jedoch häufig nicht genutzt wird. Vor diesem Hintergrund wurde 2016 am Universitätsklinikum Dresden das Programm „Mama denk an mich“ (MAMADAM) entwickelt – ein interdisziplinäres, niedrigschwelliges Therapieangebot für Schwangere, Mütter und Väter mit MA-bezogener Störung (MBS). Im vorliegenden Artikel werden bisherige Evaluationsergebnisse zum MAMADAM-Programm zusammengefasst, um Wirksamkeit, Umsetzbarkeit und versorgungspolitische Relevanz zu beurteilen, Schlussfolgerungen für die Weiterentwicklung des Programms zu ziehen und künftige Forschungs- und Implementierungsstrategien aufzuzeigen. Es werden zunächst die Konzeption und Bestandteile des MAMADAM-Programms beschrieben sowie auf die methodischen Ansätze der Programm-Evaluation eingegangen. Die bisherigen Auswertungen beruhen auf naturalistischen Verlaufsbeobachtungen der ersten Patientenkohorten. Diese werden systematisch zusammengestellt und vergleichend bewertet. Bislang nahmen über 150 Eltern mit MBS am MAMADAM-Programm teil, überwiegend junge Frauen (Durchschnittsalter ~29 Jahre) und in prekären Lebensverhältnissen. Mehr als die Hälfte befand sich erstmalig in suchtspezifischer Behandlung. Hauptkonsumsubstanz war in ~65% MA. Trotz überwiegend extrinsischer Motivation (ca. 70%) und erheblicher psychosozialer Belastungen verblieben rund zwei Drittel im Programm. Depressive Störungen und unbehandelte ADHS minderten die Erfolgswahrscheinlichkeit. MAMADAM zeigt, dass selbst hochbelastete MA-Konsumierende während Schwangerschaft und Elternschaft durch ein maßgeschneidertes ambulantes Angebot erreicht werden können. Die Zusammenarbeit mit Gynäkologie, Pädiatrie, Jugendamt und Suchthilfe ermöglicht frühzeitige Integration Betroffener und gewährleistet Kinderschutz parallel zur Suchtbehandlung. Als Erfolgskriterien lassen sich das niedrigschwellige, integrative Versorgungssetting sowie die Nutzung von Elternschaft als Motivationsfaktor identifizieren. Das Programm schließt eine Versorgungslücke und sollte sowohl regional ausgeweitet als auch strukturell in die Regelversorgung integriert werden.
- 17 December 2025
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (02) , 88-96
Ergebnisse zu „Mama denk an mich“: Ein Versorgungsprogramm für methamphetaminabhängige Mütter und Väter
Zusammenfassung: Methamphetamin(MA)-Konsum hat ab etwa 2008 in einigen Regionen Deutschlands stark zugenommen, auch unter jungen Frauen im gebärfähigen Alter. Einerseits birgt MA-Konsum hohe Risiken für Mutter und Kind. Andererseits bieten Schwangerschaft und Elternschaft eine Chance, Betroffene in Therapien zu integrieren, die wegen unzureichender spezifischer Therapiemöglichkeiten jedoch häufig nicht genutzt wird. Vor diesem Hintergrund wurde 2016 am Universitätsklinikum Dresden das Programm „Mama denk an mich“ (MAMADAM) entwickelt – ein interdisziplinäres, niedrigschwelliges Therapieangebot für Schwangere, Mütter und Väter mit MA-bezogener Störung (MBS). Im vorliegenden Artikel werden bisherige Evaluationsergebnisse zum MAMADAM-Programm zusammengefasst, um Wirksamkeit, Umsetzbarkeit und versorgungspolitische Relevanz zu beurteilen, Schlussfolgerungen für die Weiterentwicklung des Programms zu ziehen und künftige Forschungs- und Implementierungsstrategien aufzuzeigen. Es werden zunächst die Konzeption und Bestandteile des MAMADAM-Programms beschrieben sowie auf die methodischen Ansätze der Programm-Evaluation eingegangen. Die bisherigen Auswertungen beruhen auf naturalistischen Verlaufsbeobachtungen der ersten Patientenkohorten. Diese werden systematisch zusammengestellt und vergleichend bewertet. Bislang nahmen über 150 Eltern mit MBS am MAMADAM-Programm teil, überwiegend junge Frauen (Durchschnittsalter ~29 Jahre) und in prekären Lebensverhältnissen. Mehr als die Hälfte befand sich erstmalig in suchtspezifischer Behandlung. Hauptkonsumsubstanz war in ~65% MA. Trotz überwiegend extrinsischer Motivation (ca. 70%) und erheblicher psychosozialer Belastungen verblieben rund zwei Drittel im Programm. Depressive Störungen und unbehandelte ADHS minderten die Erfolgswahrscheinlichkeit. MAMADAM zeigt, dass selbst hochbelastete MA-Konsumierende während Schwangerschaft und Elternschaft durch ein maßgeschneidertes ambulantes Angebot erreicht werden können. Die Zusammenarbeit mit Gynäkologie, Pädiatrie, Jugendamt und Suchthilfe ermöglicht frühzeitige Integration Betroffener und gewährleistet Kinderschutz parallel zur Suchtbehandlung. Als Erfolgskriterien lassen sich das niedrigschwellige, integrative Versorgungssetting sowie die Nutzung von Elternschaft als Motivationsfaktor identifizieren. Das Programm schließt eine Versorgungslücke und sollte sowohl regional ausgeweitet als auch strukturell in die Regelversorgung integriert werden.
- Open Access
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Sustained abstinence after a methamphetamine-specific treatment program for pregnant and parenting women
The treatment of methamphetamine use disorder (MUD) poses a significant challenge due to high rates of treatment discontinuation, substance use recurrence, and socioeconomic adversity. ‘Mummy, think of me’ (MAMADAM, an acronym from the German “Mama, denk an mich”), a treatment program specifically designed for pregnant women and young mothers with substance use disorders, has shown positive results regarding treatment efficacy and retention of child custody. This study aimed to evaluate the long-term sustainability of the MAMADAM intervention, which has not yet been examined. For this retrospective follow-up study, former patients with MUD who were pregnant and/or parenting women at the time of MAMADAM treatment were contacted by telephone. We analyzed whether self-reported abstinence after discharge from MAMADAM was associated with patient characteristics at admission to MAMADAM. Of the 114 eligible women, 39 participated in the follow-up interview, on average, 4.5 years after completing MAMADAM. Of these, 16 (41%) reported sustained abstinence from all addictive substances, excluding tobacco. At 12 and 18 months after discharge from MAMADAM, 9/39 (23%) and 11/39 (28%) women, respectively, reported at least one instance of substance use, including alcohol but excluding tobacco. Women who reported recurrences of substance use were significantly more likely to have more underage children, live apart from at least one minor, and consume methamphetamine for longer before MAMADAM than women with sustained abstinence. Cox regression, controlling for the duration of MAMADAM treatment, indicated that a longer history of methamphetamine use at admission to MAMADAM was associated with a shorter period of abstinence from all addictive substances (excluding tobacco) following discharge. The MAMADAM program is effective and sustainable in supporting long-term abstinence among pregnant and parenting women with MUD, indicating that pregnancy and parenthood can serve as turning points for promoting the necessary behavioral changes for recovery from addiction. Some women remain at elevated risk of relapse due to the vulnerabilities identified in this study. Future research should investigate whether stronger collaborations with government and community agencies can help these women maintain long-term abstinence.
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessSustained abstinence after a methamphetamine-specific treatment program for pregnant and parenting women
The treatment of methamphetamine use disorder (MUD) poses a significant challenge due to high rates of treatment discontinuation, substance use recurrence, and socioeconomic adversity. ‘Mummy, think of me’ (MAMADAM, an acronym from the German “Mama, denk an mich”), a treatment program specifically designed for pregnant women and young mothers with substance use disorders, has shown positive results regarding treatment efficacy and retention of child custody. This study aimed to evaluate the long-term sustainability of the MAMADAM intervention, which has not yet been examined. For this retrospective follow-up study, former patients with MUD who were pregnant and/or parenting women at the time of MAMADAM treatment were contacted by telephone. We analyzed whether self-reported abstinence after discharge from MAMADAM was associated with patient characteristics at admission to MAMADAM. Of the 114 eligible women, 39 participated in the follow-up interview, on average, 4.5 years after completing MAMADAM. Of these, 16 (41%) reported sustained abstinence from all addictive substances, excluding tobacco. At 12 and 18 months after discharge from MAMADAM, 9/39 (23%) and 11/39 (28%) women, respectively, reported at least one instance of substance use, including alcohol but excluding tobacco. Women who reported recurrences of substance use were significantly more likely to have more underage children, live apart from at least one minor, and consume methamphetamine for longer before MAMADAM than women with sustained abstinence. Cox regression, controlling for the duration of MAMADAM treatment, indicated that a longer history of methamphetamine use at admission to MAMADAM was associated with a shorter period of abstinence from all addictive substances (excluding tobacco) following discharge. The MAMADAM program is effective and sustainable in supporting long-term abstinence among pregnant and parenting women with MUD, indicating that pregnancy and parenthood can serve as turning points for promoting the necessary behavioral changes for recovery from addiction. Some women remain at elevated risk of relapse due to the vulnerabilities identified in this study. Future research should investigate whether stronger collaborations with government and community agencies can help these women maintain long-term abstinence.
- Open Access
- 5 August 2025
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (6) , 600-604
Impulsive suicide in methamphetamine intoxication and self-reported ADHD: a case report
- 5 August 2025
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (6) , 600-604
Open AccessImpulsive suicide in methamphetamine intoxication and self-reported ADHD: a case report
- Open Access
- 22 April 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (4) , e70035
Effectiveness of Disulfiram as Adjunct to Addiction‐Focused Treatment for Persons With Severe Alcohol Use Disorder
The consumption of alcohol affects 400 million people worldwide, where it is responsible for 7% of deaths. Treatment success rates in this field remain limited. Only 15% of those who need treatment get it. Despite treatment, alcohol intake reoccurs in up to 90% of the cases. The use of disulfiram in preventing alcohol reoccurrence is attributed to its unique mechanism of action as an aversive agent, which causes the patient to experience unpleasant physical symptoms when they consume alcohol. The objective of this study is to confirm and illustrate the efficacy of disulfiram in combination with non‐pharmacological intervention for persons with severe AUD. Clinical data from 45 patients of an outpatient treatment programme, including the application of disulfiram (2011–2023) were analysed to assess abstinence rates, craving impact, and demographic factors. Moreover, our analyses aimed to identify predictors and moderators of continuous abstinence duration. The study cohort comprised patients with severe AUD and high rates of comorbidities, the majority of which were affective disorders. During treatment, 50% of patients remained abstinent for at least 1 year. No significant differences were identified in craving, sex or comorbidities compared with those who experienced a return to substance use after treatment initiation. Disulfiram underlined its efficacy and tolerability as an adjunct to addiction‐focused treatment in a typical clinical cohort of patients severely affected by AUD. Moreover, our analyses align with previous research indicating that disulfiram appears to allow patients with AUD to resist craving episodes, therefore avoiding impulsive reoccurrences of alcohol intake.
- 22 April 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (4) , e70035
Open AccessEffectiveness of Disulfiram as Adjunct to Addiction‐Focused Treatment for Persons With Severe Alcohol Use Disorder
The consumption of alcohol affects 400 million people worldwide, where it is responsible for 7% of deaths. Treatment success rates in this field remain limited. Only 15% of those who need treatment get it. Despite treatment, alcohol intake reoccurs in up to 90% of the cases. The use of disulfiram in preventing alcohol reoccurrence is attributed to its unique mechanism of action as an aversive agent, which causes the patient to experience unpleasant physical symptoms when they consume alcohol. The objective of this study is to confirm and illustrate the efficacy of disulfiram in combination with non‐pharmacological intervention for persons with severe AUD. Clinical data from 45 patients of an outpatient treatment programme, including the application of disulfiram (2011–2023) were analysed to assess abstinence rates, craving impact, and demographic factors. Moreover, our analyses aimed to identify predictors and moderators of continuous abstinence duration. The study cohort comprised patients with severe AUD and high rates of comorbidities, the majority of which were affective disorders. During treatment, 50% of patients remained abstinent for at least 1 year. No significant differences were identified in craving, sex or comorbidities compared with those who experienced a return to substance use after treatment initiation. Disulfiram underlined its efficacy and tolerability as an adjunct to addiction‐focused treatment in a typical clinical cohort of patients severely affected by AUD. Moreover, our analyses align with previous research indicating that disulfiram appears to allow patients with AUD to resist craving episodes, therefore avoiding impulsive reoccurrences of alcohol intake.
- Open Access
- 17 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Impact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram
The manifestations and progression of alcohol use disorder (AUD) are influenced by a number of contextual factors, with the current coronavirus pandemic being a significant example. This pandemic has profoundly impacted nearly all aspects of human life and has, therefore, strongly influenced patients suffering from AUD. In some cases, the pandemic has led to a reduction in severity, while in others, it has had the opposite effect. In our own work we have been investigating the negative impact of the pandemic on 45 patients with AUD who were undergoing outpatient treatment, including supervised use of disulfiram (Antabuse), in a close-knit program. A linear trend analysis demonstrated significant alterations in the retention rate over a 3-year period, encompassing the pre-pandemic, pandemic, and post-pandemic periods. During the pandemic the number of treatment cancellations virtually increased. Following the pandemic, a tendency towards the normalization of patient numbers was observed. Our data indicate a high level of vulnerability among patients with severe AUD and highlight a need for the development of alternative, possibly telemedical, treatment methods.
- 17 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessImpact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram
The manifestations and progression of alcohol use disorder (AUD) are influenced by a number of contextual factors, with the current coronavirus pandemic being a significant example. This pandemic has profoundly impacted nearly all aspects of human life and has, therefore, strongly influenced patients suffering from AUD. In some cases, the pandemic has led to a reduction in severity, while in others, it has had the opposite effect. In our own work we have been investigating the negative impact of the pandemic on 45 patients with AUD who were undergoing outpatient treatment, including supervised use of disulfiram (Antabuse), in a close-knit program. A linear trend analysis demonstrated significant alterations in the retention rate over a 3-year period, encompassing the pre-pandemic, pandemic, and post-pandemic periods. During the pandemic the number of treatment cancellations virtually increased. Following the pandemic, a tendency towards the normalization of patient numbers was observed. Our data indicate a high level of vulnerability among patients with severe AUD and highlight a need for the development of alternative, possibly telemedical, treatment methods.
- Open Access
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Clinical and Treatment Characteristics of 3795 Adults Consecutively Hospitalized for Major Depressive Disorder in the OASIS‐D Study
Background: Major depressive disorder (MDD) is common and associated with high social and economic burden. Knowledge of characteristics of hospitalized adults with MDD can help identify clinical treatment and prevention targets. Methods: The multicenter “Patient Characteristics, Validity of Clinical Diagnoses and Outcomes Associated with Suicidality in Inpatients with Symptoms of Depression” (OASIS‐D) study assessed characteristics of patients aged 18–75 years hospitalized between October 2020 and December 2024, who were admitted to a psychiatric inpatient unit for MDD at eight German centers. Baseline illness‐, treatment‐, and suicidality‐related characteristics of the overall sample are reported. Results: Among 3795 patients (median age = 42.0, interquartile range [IQR] = 27.5–57.0 years; females = 53.9%) with MDD (severe episode = 75.3%, psychotic features = 7.9%; first episode = 34.9%; treatment‐resistant depression [TRD] = 18.2%). Psychiatric comorbidities of MDD were present in 46.2% and included substance use disorder (18.9%), personality disorders (8.4%), stress/adjustment disorders (7.6%), and phobic/other anxiety disorders (6.6%). In 42.5%, the admission was prompted by a psychiatric emergency, primarily due to suicidality (35.0%), followed by stupor/refusal/intoxication/acute agitation (0.9%–1.5%), or danger to others/delirium (0.1%–0.3%). Overall, 72.0% of patients had active or passive suicidal thoughts, and 11.5% had attempted suicide within 2 weeks prior to admission. Furthermore, 83.9% had lifetime suicidal thoughts, and 36.0% had lifetime suicide attempts. Altogether, 76.8% had received outpatient psychiatric care within their lifetime (62.3% within 6 months), and 57.8% of patients had lifetime inpatient treatment for MDD. At admission, 71.6% of patients were prescribed psychiatric medications: antidepressants = 59.8%; antipsychotic = 25.1%, anxiolytics/hypnotics = 11.8%, and mood stabilizers = 8.6%. Additionally, 4.0% had previously received electroconvulsive therapy (ECT). The median hospitalization duration was 31.0 (IQR = 13.0, 57.0) days. Conclusion: Almost half of admissions in adults with MDD were considered emergencies, with 90% being related to suicidality, and only Trial Registration: ClinicalTrials.gov identifier: NCT04404309
- 1 January 2025
- Published by Wiley in Depression and Anxiety
- Vol. 2025 (1)
Open AccessClinical and Treatment Characteristics of 3795 Adults Consecutively Hospitalized for Major Depressive Disorder in the OASIS‐D Study
Background: Major depressive disorder (MDD) is common and associated with high social and economic burden. Knowledge of characteristics of hospitalized adults with MDD can help identify clinical treatment and prevention targets. Methods: The multicenter “Patient Characteristics, Validity of Clinical Diagnoses and Outcomes Associated with Suicidality in Inpatients with Symptoms of Depression” (OASIS‐D) study assessed characteristics of patients aged 18–75 years hospitalized between October 2020 and December 2024, who were admitted to a psychiatric inpatient unit for MDD at eight German centers. Baseline illness‐, treatment‐, and suicidality‐related characteristics of the overall sample are reported. Results: Among 3795 patients (median age = 42.0, interquartile range [IQR] = 27.5–57.0 years; females = 53.9%) with MDD (severe episode = 75.3%, psychotic features = 7.9%; first episode = 34.9%; treatment‐resistant depression [TRD] = 18.2%). Psychiatric comorbidities of MDD were present in 46.2% and included substance use disorder (18.9%), personality disorders (8.4%), stress/adjustment disorders (7.6%), and phobic/other anxiety disorders (6.6%). In 42.5%, the admission was prompted by a psychiatric emergency, primarily due to suicidality (35.0%), followed by stupor/refusal/intoxication/acute agitation (0.9%–1.5%), or danger to others/delirium (0.1%–0.3%). Overall, 72.0% of patients had active or passive suicidal thoughts, and 11.5% had attempted suicide within 2 weeks prior to admission. Furthermore, 83.9% had lifetime suicidal thoughts, and 36.0% had lifetime suicide attempts. Altogether, 76.8% had received outpatient psychiatric care within their lifetime (62.3% within 6 months), and 57.8% of patients had lifetime inpatient treatment for MDD. At admission, 71.6% of patients were prescribed psychiatric medications: antidepressants = 59.8%; antipsychotic = 25.1%, anxiolytics/hypnotics = 11.8%, and mood stabilizers = 8.6%. Additionally, 4.0% had previously received electroconvulsive therapy (ECT). The median hospitalization duration was 31.0 (IQR = 13.0, 57.0) days. Conclusion: Almost half of admissions in adults with MDD were considered emergencies, with 90% being related to suicidality, and only Trial Registration: ClinicalTrials.gov identifier: NCT04404309
- Open Access
- 2 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-5
Regaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports
Background: Alcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking. Case Presentations: A 41-year-old patient with a history of severe AUD successfully reduced his alcohol consumption to a low-risk level by leveraging the effects of the disulfiram-alcohol aversive reaction. Another patient, a 63-year-old woman with long histories of AUD and major depressive disorder, experienced fewer depressive episodes and hospitalizations with disulfiram therapy despite periodically intentional discontinuation of medication. Conclusion: Individualized treatment strategies are critical in optimizing outcomes for patients with AUD. Continuous disulfiram therapy, despite its limitations in directly reducing alcohol intake, might offer a new avenue for harm reduction in exceptional cases even if alcohol consumption continues. The cases suggest that maintaining therapy, aiming at reduced drinking, can enhance the therapeutic alliance and help manage comorbid conditions. Regular medical monitoring is essential for safety and efficacy, warranting further study of possible long-term consequences and psychotropic effects of elevated acetaldehyde levels related to the disulfiram-alcohol interaction.
- 2 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-5
Open AccessRegaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports
Background: Alcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking. Case Presentations: A 41-year-old patient with a history of severe AUD successfully reduced his alcohol consumption to a low-risk level by leveraging the effects of the disulfiram-alcohol aversive reaction. Another patient, a 63-year-old woman with long histories of AUD and major depressive disorder, experienced fewer depressive episodes and hospitalizations with disulfiram therapy despite periodically intentional discontinuation of medication. Conclusion: Individualized treatment strategies are critical in optimizing outcomes for patients with AUD. Continuous disulfiram therapy, despite its limitations in directly reducing alcohol intake, might offer a new avenue for harm reduction in exceptional cases even if alcohol consumption continues. The cases suggest that maintaining therapy, aiming at reduced drinking, can enhance the therapeutic alliance and help manage comorbid conditions. Regular medical monitoring is essential for safety and efficacy, warranting further study of possible long-term consequences and psychotropic effects of elevated acetaldehyde levels related to the disulfiram-alcohol interaction.
- 8 May 2023
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 50 (06) , 316-320
Verlaufsevaluation eines multimodalen Therapieprogrammes für Methamphetamin-konsumierende Schwangere, Mütter und Väter
Zusammenfassung: Ziel Verlaufsevaluation des suchttherapeutischen Teils des multimodalen Therapieprogramms „Mama Denk an mich“, einer interdisziplinären Zusammenarbeit mehrerer Kliniken des Universitätsklinikums Dresden mit den örtlichen Jugendämtern und Suchtberatungsstellen. Methode Behandlungsverlaufs- und Stichprobenbeschreibung der ersten 100 Patienten mit einer metamphetaminbezogenen Störung und prospektive Beobachtungsstudie der Therapieergebnisse. Ergebnisse Neben einem hohen Anteil an Erstbehandelten (51%) und einem jungen Durchschnittsalter (29 Jahre) fiel die Stichprobe durch prekäre sozioökonomische Verhältnisse und zahlreiche Komorbiditäten auf. Dennoch lässt die hohe Adhärenzrate (68%) auf eine gute Wirksamkeit der verwendeten Therapiemethoden schließen. Schlussfolgerung Eltern- bzw. Schwangerschaft stellen eine Gelegenheit dar, selbst schwere Fälle von Methamphetaminabhängigkeit mit psychiatrischen Komorbiditäten für eine wirksame ambulante Suchttherapie zu motivieren.
- 8 May 2023
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 50 (06) , 316-320
Verlaufsevaluation eines multimodalen Therapieprogrammes für Methamphetamin-konsumierende Schwangere, Mütter und Väter
Zusammenfassung: Ziel Verlaufsevaluation des suchttherapeutischen Teils des multimodalen Therapieprogramms „Mama Denk an mich“, einer interdisziplinären Zusammenarbeit mehrerer Kliniken des Universitätsklinikums Dresden mit den örtlichen Jugendämtern und Suchtberatungsstellen. Methode Behandlungsverlaufs- und Stichprobenbeschreibung der ersten 100 Patienten mit einer metamphetaminbezogenen Störung und prospektive Beobachtungsstudie der Therapieergebnisse. Ergebnisse Neben einem hohen Anteil an Erstbehandelten (51%) und einem jungen Durchschnittsalter (29 Jahre) fiel die Stichprobe durch prekäre sozioökonomische Verhältnisse und zahlreiche Komorbiditäten auf. Dennoch lässt die hohe Adhärenzrate (68%) auf eine gute Wirksamkeit der verwendeten Therapiemethoden schließen. Schlussfolgerung Eltern- bzw. Schwangerschaft stellen eine Gelegenheit dar, selbst schwere Fälle von Methamphetaminabhängigkeit mit psychiatrischen Komorbiditäten für eine wirksame ambulante Suchttherapie zu motivieren.